Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06232226
Recruiting Not applicable

Attention Deficit Hyperactivity Disorder

NCT06232226 · tracked via the Priya Life Science France tracker
Sponsor
Nantes University Hospital
Phase
Not applicable
Started
2024-04-11
Last updated
2026-04-17

Condition(s) studied

Attention Deficit Hyperactivity DisorderBehavior HyperactiveBehavior Disorders

Investigational drug(s) / intervention(s)

Patients suffering from the co-occurrence of ADHD and addiction(s)

Patients suffering from the co-occurrence of ADHD and addiction(s): All eligible patients over 18 years, presenting both a diagnosis of ADHD and a diagnosis of at least one addictive disorder (SUD, AUD (Alcohol Use Disorder) and/ or behavioral addiction), starting care in one of the three participating centers, and meeting the indication for treatment with MPH according to European recommendations (J. J. S. Kooij et al., 2019)

Study summary

The ADA cohort aims for the systematic and standardized collection of sociodemographic, clinical and neuropsychological data, during 2 visits (inclusion and 12 months), from patients suffering from the co-occurrence of ADHD (Attention Deficit Hyperactivity Disorder) and addiction(s), in addition to the treatment as usual adapted to each situation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria : * Patients aged over 18 years * For whom a diagnosis of ADHD has been confirmed less than 12 weeks ago * For whom the diagnosis of one or more addictive disorder(s) (substance use disorder or behavioral addiction) has been confirmed * Meeting the indication for treatment with MPH according to European recommendations (Kooij et al., 2019) * For patients who can actually benefit from MPH: who have not yet started taking MPH * Social security affiliates Exclusion Criteria : * Presenting disorders of higher cognitive functions (at the discretion of the referring clinician or the investigator making the inclusion), making data collection impossible * Presenting difficulties in reading or writing the French language making data collection impossible * Unable to commit to being available for the 2 visits planned as part of the cohort * Under guardianship or legal protection * Patients who have used psychoactive substances within 12 hours prior to their visit

Primary outcome measure(s)

  • Functional impairment — Inclusion and 12-month follow-up
    Weiss Functional Impairment Rating Scale (WFIRS-S) (scores of the 7 domains and total score)

Trial sites (3)

FacilityCityRegionStatus
Nantes University Hospital Nantes Loire-Atlantique Recruiting
CHRU de Brest Brest France Recruiting
CHRU de Tours Tours France Recruiting

More Nantes University Hospital trials in France

Pilot Study on the Adaptation and Tolerance of Essilor® Myopia-control Spectacle Lenses Recruiting
Characterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects Recruiting
French Clinical Datbase of Melanoma Patients (RIC-Mel) Recruiting
Research Project on the Risk of Discomfort, Pain, Alteration of Skin Condition in Bedpan Use by Patients and Caregivers Recruiting
Optimization of Skin Preparation to Reduce Cutibacterium Acnes Colonization in Superficial and Deep Samples During Prosthetic Shoulder Surgery in Male Patients Recruiting

Other trials for the same condition

Clinical Efficacy and Long Term Effects of Transcranial Direct Current Stimulation (tDCS) in Children With Attention Deficit/Hyperactivity Disorder (ADHD) Recruiting
Characterization of Social Cognition Profiles in Children and Adolescents With Neurodevelopmental Disorders: a Clinical Study Using a Multidimensional Battery Recruiting
Evaluation of Safe Use of SECURIDRAP® SELFIA® Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06232226 on ClinicalTrials.gov ↗ ← All trials in France